SCHEMBL2461097

SCHEMBL2461097

NN1Cc2ccccc2C1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.63
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
PKM P14618 3/20 0.49
ALOX15 P16050 3/20 0.46
KDM4E B2RXH2 3/20 0.46
TSHR P16473 2/20 0.46
SIRT1 Q96EB6 1/20 0.46
RNASEH1 O60930 1/20 0.46
ALDH1A1 P00352 1/20 0.45
XIAP P98170 1/20 0.45
HKDC1 Q2TB90 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CYP11B2 P19099 1/20 0.45
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.43
TLR9 Q9NR96 1/20 0.43
CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31019490 1.00 KMT2A (0.63) KMT2ANPC1RAB9APKMALOX15
Hydrochloric Acid SCHEMBL3748099 0.98 KMT2A (0.61) KMT2ANPC1RAB9APKMALOX15
SCHEMBL11407629 0.79 BCAT2 (0.50) KMT2ANPC1RAB9APKMRNASEH1
SCHEMBL31019547 0.79 BCAT2 (0.50) KMT2ANPC1RAB9APKMRNASEH1
Hydrochloric Acid SCHEMBL11413530 0.78 BCAT2 (0.49) KMT2ANPC1RAB9ARNASEH1ALDH1A1
Diftalone SCHEMBL29644941 0.77 KMT2A (1.00) KMT2ANPC1RAB9APKMALOX15
Diftalone SCHEMBL35351 0.77 KMT2A (1.00) KMT2ANPC1RAB9APKMALOX15
SCHEMBL9225134 0.76 CYP2A6 (0.55) KMT2ANPC1RAB9ARNASEH1ALDH1A1
SCHEMBL24143154 0.74 KMT2A (0.42) KMT2ANPC1RAB9APKMALOX15
SCHEMBL3169575 0.74 KMT2A (0.63) KMT2ANPC1RAB9APKMALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109983027-A Based on CEREBLON can heterodimerization Chimeric antigen receptor 细胞基因公司 2019-07-05 CN claimed
WO-2024137852-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-06-27 WO disclosed
US-20230346951-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS YALE UNIVERSITY 2023-11-02 US disclosed
WO-2023074780-A1 THERAPEUTIC AGENT COMPOSITION 国立大学法人愛媛大学 2023-05-04 WO disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 WO disclosed
WO-2018056453-A1 PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECT 中外製薬株式会社 2018-03-29 WO disclosed
EP-2768822-B1 DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS CHIESI FARM SPA (IT) 2017-12-06 EP disclosed
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR SHIONOGI & CO., LTD. (JP) 2017-09-07 US disclosed
EP-2100605-B9 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer SYNTA PHARMACEUTICALS CORP (US) 2012-05-09 EP disclosed
EP-2100605-B1 Bis(thio-hydrazide amide) compounds in combination with taxol for treating cancer SYNTA PHARMACEUTICALS CORP (US) 2011-09-07 EP disclosed
WO-2004007481-A2 SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATES DISORDERS AMGEN INC. (US) 2004-01-22 WO disclosed
EP-1242413-A4 SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-ALPHA LEVELS CELGENE CORP (US) 2003-04-23 EP disclosed
US-20030069225-A1 Synthesis of taxol enhancers SHIONOGI BIORESEARCH CORP. 2003-04-10 US disclosed
US-20030045518-A1 Taxol enhancer compounds SHIONOGI BIORESEARCH CORP. (US) 2003-03-06 US disclosed
WO-2003006428-A1 TAXOL ENHANCER COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2003-01-23 WO disclosed
WO-2003006429-A1 SYNTHESIS OF TAXOL ENHANCERS SYNTA PHARMACEUTICALS CORP. (US) 2003-01-23 WO disclosed
EP-1242413-A1 SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-ALPHA LEVELS CELGENE CORPORATION (US) 2002-09-25 EP disclosed
US-6326388-B1 ANTIINFLAMMATORY AGENTS CELGENE CORPORATION 2001-12-04 US disclosed
WO-2001046183-A1 SUBSTITUTED 1,3,4-OXADIAZOLES AND A METHOD OF REDUCING TNF-α LEVELS CELGENE CORPORATION (US) 2001-06-28 WO disclosed
US-4065462-A ORGANIC PIGMENTS CIBA-GEIGY CORPORATION (US) 1977-12-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045518-A1 Taxol enhancer compounds CCNY, CENPE, CCR1 KMT2A 1501/4885NPC1 411/4885RAB9A 1846/4885
US-20230346951-A1 MOLECULAR DEGRADERS OF EXTRACELLULAR PROTEINS ASGR1, MSR1, LDLR KMT2A 4686/4885NPC1 1470/4885RAB9A 1971/4885
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR CPN1, HAT1, PRSS1 KMT2A 1478/4885NPC1 1693/4885RAB9A 4095/4885
US-20030069225-A1 Synthesis of taxol enhancers TOP2B, TUBB1, TUBA1B KMT2A 2090/4885NPC1 1060/4885RAB9A 1901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.